Omeros posts Q4 net loss $9.1M, secures $115.5M from OMIDRIA royalty sale

OMEROS CORP

2025-Q1 EPS reported -$0.63

Q4 2023 net loss $9.1M ($0.15/sh) vs Q3 loss $37.8M; full-year net loss $117.8M ($1.88/sh) vs prior-year net income $47.4M.
Amended OMIDRIA royalty deal with DRI: received $115.5M; DRI gets all U.S. royalties through 2031; Omeros retains ex-U.S. & post-2031 global royalties; potential $55M milestones.
Cash and investments $171.8M at Dec 31, 2023; plus $115.5M from DRI in Feb 2024; expects ~$230M at Mar 31, 2024 after share repurchases.
Narsoplimab BLA resubmission in TA-TMA still under FDA discussion; unable to estimate timing for submission or approval.
OMS906 Phase 2 trials in PNH fully enrolled; positive interim data; Phase 3 targeted late 2024; OMS1029 Phase 1 multiple-ascending dose completed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OMEROS CORP reported the fourth quarter and year ended December 31, 2023 results: net income Net loss for the fourth quarter of 2023 was $9.1 million, or $0.15 per share, EPS net loss of $117.8 million, or $1.88 per share.

Period: the fourth quarter and year ended December 31, 2023
Net income: Net loss for the fourth quarter of 2023 was $9.1 million, or $0.15 per share
EPS: net loss of $117.8 million, or $1.88 per share
Result: reported results

Exact text from the filing

Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2023, which include: ● Net loss for the fourth quarter of 2023 was $9.1 million, or $0.15 per share, compared to a net loss of $37.8 million, or $0.60 per share for the third quarter of 2023. Net loss from continuing operations was $39.3 million for the 2023 fourth quarter compared to $51.7 million for the prior quarter. ● For the year ended December 31, 2023, net loss was $117.8 million, or $1.88 per share, compared to net income of $47.4 million, or $0.76 per share, in the prior year.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

OMEROS CORP filing history →

Source: SEC EDGAR

accession 0001437749-24-010359

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.